Drug Co. Atara Hit With Investor Suit Over FDA Denial

By Sydney Price · March 24, 2026, 8:27 PM EDT

Drug company Atara Biotherapeutics Inc. has been hit with a proposed class action accusing it of harming investors by not disclosing certain manufacturing problems and research study deficiencies that made it...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Kuang v. Atara Biotherapeutics, Inc. et al

Case Number

Court

California Central

Nature of Suit

Securities/Commodities

Date Filed

March 23, 2026

Recent Articles By Sydney

March 23, 2026
Revance Investors Ink $17M Deal In Take-Private Offer Suit
March 20, 2026
Hims Says Failed Wegovy Collab Doesn't Merit Investor Suit
March 18, 2026
SelectQuote Looks To Escape Investors' Kickback Probe Suit
March 05, 2026
Drugmaker Aquestive Hit With Suit Over FDA Approval Delay
March 03, 2026
BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit
February 03, 2026
Masimo Investors' $34M Deal In Revenue Suit Gets Initial OK
January 30, 2026
SelectQuote Execs Face Investor Suit Over Kickback Probe
January 16, 2026
SEC Fines Biopharma Co. Execs Over Hidden FDA Findings
January 16, 2026
Lifecore Investors Ink $3.8M Deal In Accounting Controls Suit
January 09, 2026
Ex-Doximity Exec Cops To $2.5M Insider Trading Scheme